Clostridium Difficile Infections Pipeline Landscape Analysis of 25+ Companies by DelveInsight | Leading Players – Rebiotix, Seres Therapeutics, Acurx Pharmaceuticals, and Others

October 10 23:05 2022
Clostridium Difficile Infections Pipeline Landscape Analysis of 25+ Companies by DelveInsight | Leading Players - Rebiotix, Seres Therapeutics, Acurx Pharmaceuticals, and Others

DelveInsight’s, “Clostridium Difficile Infections Pipeline Insight, 2022” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Clostridium Difficile Infections (Clostridium Difficile Associated Disease) pipeline landscape.

 

Clostridium Difficile Infections Pipeline Insight, 2022″ report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Clostridium Difficile Infections pipeline landscape is provided which includes the disease overview and Clostridium Difficile Infections treatment guidelines. The assessment part of the report embraces, in depth Vascular Dementia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Clostridium Difficile Infections collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Key takeaways from the Clostridium Difficile Infections Pipeline Report

  • DelveInsight’s Clostridium Difficile Infections pipeline report depicts a robust space with 25+ active players working to develop 25+ pipeline therapies for Clostridium Difficile Infections treatment.
  • Leading Clostridium Difficile Infections Companies such as Rebiotix, Seres Therapeutics, Acurx Pharmaceuticals, Adiso Therapeutics, Summit Therapeutics, Finch Therapeutics Group, Mikrobiomik Healthcare Company S.L., Crestone, MGB Biopharma, Vedanta Biosciences, Inc., Deinove, Biovertis AG, Lumen Bioscience, and others
  • The promising Clostridium Difficile Infections therapies such as Fidaxomicin, DAV132, RBX2660, SER-109, Ridinilazole, MK-6072, MK-3415A, and others
  • The Clostridium Difficile Infections Companies and academics are working to assess challenges and seek opportunities that could influence Clostridium Difficile Infections R&D. The therapies under development are focused on novel approaches to treat/improve Clostridium Difficile Infections.
  • The Clostridium Difficile Infections Pipeline Report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage.

 

Latest Breakthroughs and Developments in the Clostridium Difficile Infections Treatment Landscape

  • Rebiotix Inc., a Ferring Company, has conducted several trials of the lead microbiota-based product in the MRT™ drug platform, RBX2660, for reducing the rate of recurrence of Clostridioides difficile infection. RBX2660 is currently under study in a Phase 3 clinical trial in conjunction with the US Food and Drug Administration’s Investigational New Drug application.
  • SER-109 is a first-in-class investigational microbiome therapeutic administered orally following antibiotics to reduce recurrence of C. difficile infection (CDI) in patients with recurrent CDI. SER-109 is comprised of purified Firmicutes spores, based on their modulatory role in the life cycle of C. difficile and disease pathogenesis. The FDA has granted SER-109 Breakthrough Therapy Designation and Orphan Drug Designation. In a Phase 3 clinical trial, SER-109 achieved high rates of sustained clinical responses with a favorable safety profile comparable to placebo in patients with recurrent CDI.
  • Ibezapolstat (formerly named ACX-362E) is our lead antibiotic candidate. Ibezapolstat is a first-in-class of a new class of Pol IIIC inhibitors which is in clinical development to treat C. difficile infections or CDI. Current treatments for CDI infections utilize other mechanisms of action while ibezapolstat is the first antibiotic candidate intended to work by blocking the Pol IIIC enzyme in C. difficile. This enzyme is necessary for replication of the DNA of the DNA of the bacterial cell.
  • ADS024 is an oral single strain live biotherapeutic product (SS-LBP). A naturally occurring live biotherapeutic product, ADS024 possesses a dual mechanism of action. It is bactericidal toward Clostridioides difficile and degrades Toxins A and B produced by C. difficile while maintaining other components of the microbiome. ADS024 is a single strain multimodal LBP and is manufactured from a pure, clonal bacterial cell bank, yielding a standardized lyophilized drug product eliminating the need to directly source from donor fecal material.

 

Request a Sample Copy and discover the recent advances in Clostridium Difficile Infections Pipeline Report @ Clostridium Difficile Infections Pipeline Outlook

 

Clostridium Difficile Infections Overview

Clostridium difficile infection (CDI) is acute diarrhea and colitis that is most often preceded by antimicrobial use and is caused by an anaerobic spore-forming, toxin-producing bacterium. C. difficile is found in water, soil, meats, and vegetables and is particularly common in health care environments, where the spores are difficult to eradicate. Patients are exposed to and ingest C. difficile spores in the health care setting from contact with the environment or health care workers who do not practice good hand hygiene. Clostridium difficile infection is the most common cause of hospital acquired diarrhea and carries significant morbidity and mortality. Current treatment options are limited by high rates of recurrence, and fecal transplantation has proven to be an effective and safe option, with very low rates of recurrence. Initial treatment of CDI involves discontinuation of any nonvital antibiotic therapy and administration of fluid and electrolyte replacement.

 

Clostridium Difficile Infections Pipeline Insight

“Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Pipeline Insight, 2022″ report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Clostridium Difficile Infections (Clostridium Difficile Associated Disease) pipeline landscape is provided which includes the disease overview and Clostridium Difficile Infections (Clostridium Difficile Associated Disease) treatment guidelines. The assessment part of the report embraces, in depth Clostridium Difficile Infections (Clostridium Difficile Associated Disease) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Clostridium Difficile Infections(Clostridium Difficile Associated Disease) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Clostridium Difficile Infections Emerging Drugs

  • RBX 2660: Rebiotix
  • SER 109: Seres Therapeutics
  • Ibezapolstat: Acurx Pharmaceuticals
  • ADS 024: Adiso Therapeutics

 

Learn more about the novel and emerging Clostridium Difficile Infections pipeline therapies @ Clostridium Difficile Infections Clinical Trials

 

DelveInsight’s Clostridium Difficile Infections Pipeline Phases Report covers around 25+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Clostridium Difficile Infections Route of Administration

Products have been categorized under various ROAs such as

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal

 

Clostridium Difficile Infections Molecule Type

Products have been categorized under various Molecule types such as

  • Oligonucleotide
  • Peptide
  • Small molecule

 

Read for more information about the Clostridium Difficile Infections Pipeline Report @ Clostridium Difficile Infections Emerging Therapies

 

Scope of the Clostridium Difficile Infections Pipeline Report

  • Coverage- Global
  • Clostridium Difficile Infections Companies- Rebiotix, Seres Therapeutics, Acurx Pharmaceuticals, Adiso Therapeutics, Summit Therapeutics, Finch Therapeutics Group, Mikrobiomik Healthcare Company S.L., Crestone, MGB Biopharma, Vedanta Biosciences, Inc., Deinove, Biovertis AG, Lumen Bioscience, and others
  • Clostridium Difficile Infections Therapies- Fidaxomicin, DAV132, RBX2660, SER-109, Ridinilazole, MK-6072, MK-3415A, and others
  • Clostridium Difficile Infections TherapeuticsAssessment by Product Type
  • Clostridium Difficile Infections TherapeuticsAssessment by Stage and Product Type
  • Clostridium Difficile Infections TherapeuticsAssessment by Route of Administration
  • Clostridium Difficile Infections TherapeuticsAssessment by Stage and Route of Administration
  • Clostridium Difficile Infections TherapeuticsAssessment by Molecule Type
  • Clostridium Difficile Infections TherapeuticsAssessment by Stage and Molecule Type

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Clostridium Difficile Infections (Clostridium Difficile Associated Disease): Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Clostridium Difficile Infections(Clostridium Difficile Associated Disease)– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Pre-Registration)
  8. RBX 2660: Rebiotix
  9. Mid Stage Products (Phase II)
  10. Ibezapolstat: Acurx Pharmaceuticals
  11. Early Stage Products (Phase I)
  12. ADS 024: Adiso Therapeutics
  13. Preclinical and Discovery Stage Products
  14. Drug Name: Company Name
  15. Inactive Products
  16. Clostridium Difficile Infections Key Companies
  17. Clostridium Difficile Infections Key Products
  18. Clostridium Difficile Infections – Unmet Needs
  19. Clostridium Difficile Infections – Market Drivers and Barriers
  20. Clostridium Difficile Infections – Future Perspectives and Conclusion
  21. Clostridium Difficile Infections Analyst Views
  22. Clostridium Difficile Infections Key Companies
  23. Appendix

 

For further information on the Clostridium Difficile Infections Pipeline therapeutics, reach out to Clostridium Difficile Infections Drugs

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/